Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Single-Dose Aripiprazole IM Depot in Chinese Patients with Schizophrenia
NCT03287505Phase 1Completed
- Sponsor
- Otsuka Holdings
- Start
- Jun 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of aripiprazole in schizophrenia (2 arms), sponsored by Otsuka Holdings. Primary endpoints: Maximum Plasma Concentration up to 20 weeks, Time of Maximum Concentration up to 20 weeks and 2 more. Started Jun 2017; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03287505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287505.